Introduction: Atypical Antipsychotics (AAPs) are approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder. AAPs are commonly used off-label to treat depression, post-traumatic stress disorder and neuropsychiatric symptoms in dementia due to lack of alternative treatment options and treatment resistance. Concerns for off-label use arise since AAPs increase the risk of cardiovascular events and death. The objectives were 1) describe patterns of RU and costs among off-label AAPs users in a nationally representative population 2) identify prevalence of off-label use in the Medicare population 3) compare RU and costs between off-label AAPs users and non-users with mental health conditions in Medicare. Methods: For the first objective, the Medical Expenditure Panel Survey (MEPS) datasets were used. AAPs users greater than 18 years were identified in this cross-sectional study. Generalized Linear Models (GLM) were used to estimate costs among users and non-users after controlling for age sex, gender, insurance type, marriage status, income and comorbidity index. For the second and third objective, Medicare datasets were used to identify prevalence, RU, and costs of off-label use in Medicare beneficiaries 18 years and older. RU and costs between propensity score matched AAPs user and non-user cohorts were compared in a retrospective cohort study. Results: The adjusted odds of having an office-based outpatient (OR=2.47, 95%CI: 1.55-3.92) or inpatient (OR=1.63, 95%CI: 1.26-2.10) visit were significantly higher among off-label AAPs users. Adjusted office-based visit ($1,943 vs. $1,346), prescription ($4,153 vs. $1,252) and total ($10,694 vs. $4,823) costs were significantly higher among users (p<0.0001). Among Medicare beneficiaries, approximately 37% of AAPs users had no FDA approved diagnosis. The typical off-label user was a white 70-year-old male. Common off-label uses were depression, anxiety and neurotic disorders and dementia. Off-label AAPs users had significantly higher mental health outpatient ($461 vs $297), prescription ($2,349 vs $282) and total ($3,665 vs $1,297) costs per beneficiary than non-users. About 30% of AAPs users had at least one mental health outpatient visit during the year versus 23% of non-users; no significant differences were found in inpatient visits. AAPs non-users had significantly higher all-cause inpatient costs ($6,945 vs. $4,841) per beneficiary (p Conclusion: In a nationally representative population comprising a younger age group AAPs users had higher all-cause RU and total costs than non-users. Off-label prescribing of AAPs continued to be a prevalent practice affecting 37% of Medicare AAPs users. Off-label AAPs users had higher mental health costs but no significant differences in all-cause total health care costs in a Medicare population. Off-label use of AAPs can be a cost-effective option if future research shows off-label use is associated with increased effectiveness, which offsets any additional costs.

The objective of this dissertation is to evaluate whether two different types of policy interventions in the United States are associated with health service utilization and economic outcomes. Paper 1: The number of government lawsuits accusing pharmaceutical companies of off-label marketing has risen in recent years. We use Medicare and Medicaid claims data to evaluate how an off-label marketing lawsuit and its accompanying media coverage affected utilization and spending on gabapentin as well as other anticonvulsant medications. In this interrupted time series analysis of dual eligible patients with bipolar disorder, we found that the lawsuit and accompanying media coverage corresponded with a decrease in market share of gabapentin, a substitution of newer and expensive anticonvulsants, and a substantial increase in overall spending on anticonvulsants. Paper 2: Medicare Part D was a major expansion of Medicare benefits to cover pharmaceuticals. There were initial concerns about how the dually eligible population who previously had drug coverage through Medicaid would fare after transitioning to Part D plans. Using a nationally representative longitudinal panel survey of Medicare Beneficiaries that are dually eligible for Medicaid, we investigated whether differences in generosity of Medicaid drug benefits were associated with differential changes in drug utilization and out-of-pocket spending for duals after they transitioned to Part D. Our finding suggest that those who previously encountered a monthly drug cap prior to Part D implementation experienced a differentially higher increase in annual prescription drug fills compared with those who did not face a cap.

Universiẗat, Diss., 2007--Düsseldorf.

FDA approval of drug-eluting stents (DES) in 2002, was based on data obtained from several pivotal, short-term (< one year) randomized control trials that evaluated their efficacy in reducing in-stent restenosis when used in treatment of coronary artery lesions compared with bare metal stents (BMS). These trials excluded patients with complex coronary lesions. When the FDA approved use of DES in treatment of coronary artery lesions, the on-label indications only applied to a very limited subset of simple lesions. Immediate advantages of DES were observed in clinical practice for on-label indications, specifically in their ability to significantly reduce in-stent restenosis after PCI. The increased short-term safety and efficacy seen in on-label clinical cases soon led clinicians to expand the use DES to more complex lesions. These complex indications, not included in the pivotal FDA trials, are considered off-label. Off-label indications include bifurcation lesions, ostial lesions, lesions greater in length and diameter than those approved by the FDA, implantation in saphenous vein grafts, and lesions in the left main coronary artery. Currently, DES use for treatment of lesions presenting off-label indications may comprise as much as 60% of clinical cases. However, early evidence that DES may play a role in adverse safety outcomes, has led many to question the use of DES outside their on-label indications. This paper sought to evaluate some of the current research investigating first generation DES use in four different off-label indications: coronary artery bypass graft lesions, saphenous vein graft lesions, ostial lesions, and chronic total coronary occlusions. In particular, it looked at studies, which compared the efficacy and clinical outcomes of DES and BMS treatment of each of the different lesion types. The results of this evaluation were very promising in that of the four specific off-label indications evaluated, all of them showed to be superior in reduction of neointimal growth and subsequent in-stent restenosis. Additionally, DES treatment of left main coronary artery lesions, saphenous vein graft lesions, and chronic total coronary occlusions showed to be superior in reducing the incidence rate of major adverse cardiac events and target vessel revascularization over various follow-up durations. The only scenario that DES did not prove to be superior to BMSs was the treatment of ostial lesions. Long-term randomized control trials with large study populations should be performed to further elucidate the effects of DES treatment of specific off-label lesions.

Bakgrund: Eculizumab (Solirisâ) är en monoklonal antikropp som är riktad mot C5 i komplementsystemet. Bindning av eculizumab till C5 förhindrar proteinets klyvning och därmed också aktivering. Eculizumab är godkänt för behandling av atypiskt hemolytiskt uremiskt syndrom och paroxysmal nokturn hemoglobinuri. Sedan behandlingen blivit godkänd för dessa tillstånd har även ”off-label use” vid andra tillstånd varit betydande. En tidigare studie har visat att uppemot 50 % av behandling med eculizumab är off-label use, det vill säga behandling utanför de idag godkända indikationerna. Ett av dessa tillstånd är katastrofalt antifosfolipidsyndrom (KAPS), ett mycket allvarligt tillstånd som karaktäriseras av multipla tromboser som utvecklas under kort tid i flera organ vid vilket eculizumab visat sig ha en potentiellt positiv effekt. KAPS kan uppstå om man har bakomliggande antifosfolipid syndrom (APS) och kan utlösas vid en så kallad ”second hit”, en inflammatorisk stressreaktion orsakad av exempelvis en infektion eller kirurgiskt ingrepp. Eculizumab är ett särläkemedel och är en av de dyraste läkemedelsbehandlingarna i världen. Syfte: Syftet med denna studie var att analysera fall där KAPS behandlats med eculizumab för att utvärdera om eculizumab bör vara standarbehandling vid detta tillstånd. Likheter och olikheter mellan fallen studerades för att utvärdera när det kan vara lämpligt att behandla med eculizumab. Syftet var också att utvärdera detta utifrån ett ekonomiskt perspektiv. Metod: Detta är en litteraturstudie där sökningar i PubMed gjorts efter rapporter som beskriver fall där patienter med KAPS eller som ansetts haft en risk att utveckla KAPS behandlats med eculizumab. Åtta rapporter med totalt tio fall inkluderades och analyserades. Resultat: De rapporter som analyserades visade övergripande en tydlig effekt av behandling med eculizumab. Eculizumab tolkades också i vissa fall som ett kostnadseffektivt alternativ genom bland annat förkortad intensivvård och dialysbehov. Slutsats: Eculizumab har i de fall som analyserats visat sig ha en avgörande betydelse för att reversera ett livshotande tillstånd och skulle kunna vara standardbehandling vid KAPS och förebyggande av KAPS. För att eculizumab, eller en annan komplementhämmare, ska kunna bli standardbehandling krävs ytterligare forskning på KAPS och dess relation till komplementsystemet. / Catastrophic antiphospholipidsyndrome (CAPS) is a rare but highly fatal condition characterized by thrombosis in multiple organs, often associated with a rapid progression of disease and serious complications for the patient. A rapid diagnosis and treatment is therefore a key to manage this condition. The conventional treatment, which consists of anticoagulation, steroids, plasma exchange and intravenous immunoglobulins, reduces mortality but CAPS is still associated with high mortality. To find the mechanism of how and why this condition evolves is therefore important. There has been progress to find out the pathogenesis and one clue appears to be the complement system. Therefore, a new type of treatment has been used in patients who have been diagnosed with antiphosphlipidsyndrome (APS) and have had a risk of developing CAPS, or have been diagnosed with definitive or probable CAPS. This treatment is aimed at inhibiting parts of the complement system and consists of a monoclonal antibody called eculizumab. Lately eculizumab has been used off label in patients diagnosed with CAPS and in patients that has been at risk of developing CAPS. The results of this treatment have been positive and have therefore been considered as a possible alternative for treating CAPS. The aim of this study was to evaluate if eculizumab can be an alternative to treat patients with CAPS and patients diagnosed with APS who have a risk of developing CAPS. In order to evaluate treatment with eculizumab in patients with CAPS, searches on cases were done in the database PubMed for reports of patients with CAPS or at risk of developing CAPS who have been treated with eculizumab. Eight reports with a total of ten cases were found and used in order to answer the hypothesis of this study. In the ten cases that were analyzed there was a clear connection between the treatment and the recovery. In both patients with CAPS and patients at risk of developing CAPS the treatment with eculizumab was considered of significant importance. Because of the rarity of this condition, every case makes significant impact into the understanding of this potentially fatal condition. For future new cases, the present report will stand as an important source for making decisions about treatment with eculizumab. With time and more cases with positive results eculizumab has the potential to become conventional treatment for CAPS.

Introdução. Medicamentos não licenciados e sem indicação são utilizados com grande frequência em pediatria por razões éticas e econômicas. A utilização destes medicamentos não constitui um preceito ilegal, mas pode oferecer risco aos pacientes, sendo responsabilidade do médico e do farmacêutico qualquer evento adverso ocasionado. Alguns estudos nesta população sugerem aumento do risco de reações adversas relacionadas ao uso de medicamentos fora das indicações licenciadas. Objetivo. Analisar a exposição a medicamentos não licenciados e sem indicação em neonatos admitidos em Unidade de Terapia Intensiva (UTINEO) em hospital universitário de média complexidade de São Paulo, Brasil. Método. Estudo descritivo transversal dos medicamentos prescritos nas primeiras 24 horas de internação para 79 pacientes admitidos na Unidade de Terapia Intensiva Neonatal, do Hospital Universitário da Universidade de São Paulo (HU-USP), campus de São Paulo, no período de 12/03/08 a 03/11/08. Os medicamentos foram classificados em não licenciados e sem indicação para utilização por população neonatal de acordo com critérios de registro brasileiros e americanos. Resultados: foram prescritos 346 medicamentos. De acordo com os critérios brasileiros de licenciamento 58% não estavam licenciados, 9,5% não eram indicados, sendo que 66 % dos pacientes foram expostos a ao menos 1 item não licenciado e 18% a pelo menos 1 item sem indicação. A avaliação com base nos critérios americanos demonstrou que 53% dos medicamentos não estavam licenciados, 10,9% não tinham indicação, sendo que 63% dos pacientes foram expostos a ao menos 1 item não licenciado e 20% a pelo menos 1 item sem indicação.Conclusões: Os neonatos brasileiros estão expostos a medicamentos não licenciados e sem indicação nas primeiras 24 horas de internação. Embora esforços tenham sido empregados em diversos países para diminuir tal prática, o problema não foi equacionado. No Brasil, ainda, há informações distintas em bulas de medicamentos licenciados e, em relação, aos medicamentos não licenciados ou sem indicação não há nenhuma política estabelecida. / Introduction. In pediatrics utilization of unlicensed an off-label drugs are a common practice and this account for ethical and economic reasons. The utilization of unlicensed and off label drugs is not illegal, but can expose patients to risk of harm. Physicians and pharmacists have legal responsibility for any adverse event that may result from this use. Some studies in the pediatric field suggest an increased risk to adverse reactions related to unlicensed and off label use. Objective. To assess the exposure to unlicensed and off-label medicines in neonates admitted to the Neonatal Intensive Care Unit (NICU) in a Brazilian medium complexity University Hospital. Materials and Methods. A cross sectional descriptive study was conducted of prescribed medicines in the first 24 hours of admission for 79 patients admitted to the Neonatal Intensive Care Unit (NICU) in the University Hospital of the University of São Paulo (HU-USP), campus of São Paulo in the period of 12/03/08 to 03/11/08. The medicines were classified as unlicensed and off-label for use in neonatal population according to the criteria for licensing of medicines in Brazil and US. Results: There were a total of 346 medicines prescribed and according to the established criteria in Brazil 58% were unlicensed, 9.5% were off-label; 66% of patients were exposed to at least 1 item unlicensed and 18% at least 1 item off-label. In relation to the criteria in USA 53% were not licensed, 10.9% were off-label, and 63% of patients were exposed to at least 1 item unlicensed and 20% at least 1 item off-label. Conclusions: Brazilian neonates are exposed to unlicensed and off-label medicines already in the first 24 hours of hospitalization. Although efforts have been employed in several countries to reduce this practice, the problem was not solved. In Brazil, there is even different information in leaflets for medicines licensed in and, in relation, to unlicensed or off-label medicines there is no established policy.

Introdução. Medicamentos não licenciados e sem indicação são utilizados com grande frequência em pediatria por razões éticas e econômicas. A utilização destes medicamentos não constitui um preceito ilegal, mas pode oferecer risco aos pacientes, sendo responsabilidade do médico e do farmacêutico qualquer evento adverso ocasionado. Alguns estudos nesta população sugerem aumento do risco de reações adversas relacionadas ao uso de medicamentos fora das indicações licenciadas. Objetivo. Analisar a exposição a medicamentos não licenciados e sem indicação em neonatos admitidos em Unidade de Terapia Intensiva (UTINEO) em hospital universitário de média complexidade de São Paulo, Brasil. Método. Estudo descritivo transversal dos medicamentos prescritos nas primeiras 24 horas de internação para 79 pacientes admitidos na Unidade de Terapia Intensiva Neonatal, do Hospital Universitário da Universidade de São Paulo (HU-USP), campus de São Paulo, no período de 12/03/08 a 03/11/08. Os medicamentos foram classificados em não licenciados e sem indicação para utilização por população neonatal de acordo com critérios de registro brasileiros e americanos. Resultados: foram prescritos 346 medicamentos. De acordo com os critérios brasileiros de licenciamento 58% não estavam licenciados, 9,5% não eram indicados, sendo que 66 % dos pacientes foram expostos a ao menos 1 item não licenciado e 18% a pelo menos 1 item sem indicação. A avaliação com base nos critérios americanos demonstrou que 53% dos medicamentos não estavam licenciados, 10,9% não tinham indicação, sendo que 63% dos pacientes foram expostos a ao menos 1 item não licenciado e 20% a pelo menos 1 item sem indicação.Conclusões: Os neonatos brasileiros estão expostos a medicamentos não licenciados e sem indicação nas primeiras 24 horas de internação. Embora esforços tenham sido empregados em diversos países para diminuir tal prática, o problema não foi equacionado. No Brasil, ainda, há informações distintas em bulas de medicamentos licenciados e, em relação, aos medicamentos não licenciados ou sem indicação não há nenhuma política estabelecida. / Introduction. In pediatrics utilization of unlicensed an off-label drugs are a common practice and this account for ethical and economic reasons. The utilization of unlicensed and off label drugs is not illegal, but can expose patients to risk of harm. Physicians and pharmacists have legal responsibility for any adverse event that may result from this use. Some studies in the pediatric field suggest an increased risk to adverse reactions related to unlicensed and off label use. Objective. To assess the exposure to unlicensed and off-label medicines in neonates admitted to the Neonatal Intensive Care Unit (NICU) in a Brazilian medium complexity University Hospital. Materials and Methods. A cross sectional descriptive study was conducted of prescribed medicines in the first 24 hours of admission for 79 patients admitted to the Neonatal Intensive Care Unit (NICU) in the University Hospital of the University of São Paulo (HU-USP), campus of São Paulo in the period of 12/03/08 to 03/11/08. The medicines were classified as unlicensed and off-label for use in neonatal population according to the criteria for licensing of medicines in Brazil and US. Results: There were a total of 346 medicines prescribed and according to the established criteria in Brazil 58% were unlicensed, 9.5% were off-label; 66% of patients were exposed to at least 1 item unlicensed and 18% at least 1 item off-label. In relation to the criteria in USA 53% were not licensed, 10.9% were off-label, and 63% of patients were exposed to at least 1 item unlicensed and 20% at least 1 item off-label. Conclusions: Brazilian neonates are exposed to unlicensed and off-label medicines already in the first 24 hours of hospitalization. Although efforts have been employed in several countries to reduce this practice, the problem was not solved. In Brazil, there is even different information in leaflets for medicines licensed in and, in relation, to unlicensed or off-label medicines there is no established policy.

This diploma thesis focuses on drug approval efficiency. It is obvious that the drug approval process is lengthy and expensive. The question that arises is whether the length of the drug approval process, as well as associated costs, leads to better safety. The first part briefly summarizes the history of the drug regulation and the drug legislative in the Czech Republic. Also focuses on the theory of economic regulation and the theory of bureaucracy. The second part deals with the drug approval process for new drugs, describes preclinical and clinical testing in relation to the analysis of Sam Peltzman. The third part compares drug approval process in different markets. The last part summarizes off-label prescribing, especially in pediatric.

Aproximadamente apenas um terço dos medicamentos utilizados em crianças tem sido estudado de forma adequada e apresentam informações sobre eficácia e segurança do produto. Este fato se deve a dificuldade de realização de ensaios clínicos na população pediátrica tornando-a mais propensa a erros de medicação, predominantemente devido à necessidade de prescrições de apresentações farmacêuticas não aprovadas e não indicadas para uso pela indústria e agência de fiscalização sanitária. Dessa forma, uma ferramenta importante que pode ser utilizada para análise do uso de medicamentos nesta população compreende os estudos da utilização de medicamentos. O presente estudo analisou as prescrições medicamentosas realizadas para crianças hospitalizadas no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo, com a finalidade de estabelecer o perfil de utilização de medicamentos de acordo com os critérios de aprovação e indicação da Agencia Nacional de Vigilância Sanitária (ANVISA) e da Food and Drugs Administration (FDA). O estudo foi aprovado pelo Comitê de Ética em Pesquisa do respectivo hospital, e classificado como transversal, retrospectivo e observacional. Através do banco de dados informatizado, foram analisadas todas as prescrições medicamentosas a crianças menores de 12 anos no período compreendido entre 01/08/2008 a 31/07/2009. A população pediátrica foi dividida em subgrupos de acordo com os parâmetros fisiológicos do desenvolvimento estabelecidos pela Organização Mundial de Saúde. As apresentações farmacêuticas foram classificadas de acordo com o primeiro nível do sistema Anatomical Therapeutic Chemistry e, por conseguinte, foi realizada a classificação de uso das mesmas em: licenciado, não licenciado - registro, indicado, não indicado, não licenciado - dispersão e licenciado/indicado de acordo com a ANVISA e FDA. Durante o período analisado, foram identificados 6948 pacientes, 56,7% do sexo masculino, média de idade 3,1 (±3,5) anos, média de internação 17,5 (±29,8) dias, 1120 causas de internação e 79 unidades de atendimento. A causa de internação mais frequente esteve relacionada ao nascimento no hospital, sendo dessa forma, o centro obstétrico a unidade mais requisitada para hospitalização. Das 617 apresentações farmacêuticas identificadas, 17,6% foram referentes aos agentes infecciosos de uso sistêmico. A média de apresentações farmacêuticas por paciente foi de 6,1. Em relação ao uso não licenciado - registro 1,1% e 14,9% das apresentações farmacêuticas assim foram classificadas de acordo com a análise da ANVISA e FDA, respectivamente. O uso não indicado esteve presente em 36,5% e 37,3% de acordo com a ANVISA e FDA, respectivamente. Dessa forma, este trabalho ressalta a necessidade em se estabelecer um consenso sobre a classificação de uso dos medicamentos na população pediátrica entre os países, além de enfatizar a necessidade de aumentar a realização ensaios clínicos nesta população, uma vez que houve um elevado número de apresentações farmacêuticas com informações de uso apenas na população adulta sendo utilizadas em crianças / Approximately only one-third of the drugs used in children has been studied adequately and presents information about its effectiveness and safety. This fact is due to the difficulty of conducting clinical trials in the pediatric population making them more prone to medication errors, mainly due to the need for pharmaceutical dosage forms unapproved and off-label for use by industry and regulatory agency. Thus, an important tool that can be used to analyze the use of drugs in this population comprises studies of drug utilization. This study analyzed drug prescriptions for children hospitalized at the Clinical Hospital of the Faculty of Medicine of Ribeirão Preto - University of São Paulo, in order to establish the profile of drug utilization in accordance to the criteria for approval and indication of the Brazilian Regulatory Agency (ANVISA) and the Food and Drugs Administration (FDA). The study was approved by the Research Ethics Committee of the respective hospital, being classified as cross-sectional, retrospective, observational study. Through the computerized database, all drug prescriptions to children under the age of 12 were analyzed in the period of August 1st, 2008 to July 31st, 2009. The pediatric population was divided into subgroups according to the physiological parameters of development established by the World Health Organization. The pharmaceutical dosage forms were classified according to the first level of the Anatomical Therapeutic Chemistry system. Thereafter, the use of pharmaceutical dosage forms was classified as follows: licensed, unlicensed - registered, label, off-label, unlicensed - dispersion and licensed/label according to FDA and ANVISA. During the study period, 6948 patients were identified, being 56.7% male, mean age 3.1 (± 3.5) years, mean length of hospitalization 17.5 (± 29.8) days, 1120 causes of hospitalization and 79 service units. The most prevalent cause of hospital stays was related to birth at the hospital, being the obstetric center the most required unit for hospitalization. Of the 617 pharmaceutical dosage forms identified, 17.6% were related to infectious agents for systemic use. The average pharmaceutical dosage forms per patient were 6.1. Regarding the unlicensed use, 1.1% and 14.9% of the pharmaceutical dosage forms were classified according to the analysis from ANVISA and FDA, respectively. The off-label use was present in 36.5% and 37.3% according to ANVISA and FDA, respectively. This work emphasizes the need to establish a consensus on the classification of the use of drugs in the pediatric population among countries, and underline the necessity of increase the number of clinical trials performed in this population, since there were a high number of pharmaceutical dosage forms with use information only for adult populations being used in children.

Submitted by Automa??o e Estat?stica (sst@bczm.ufrn.br) on 2017-10-04T21:05:46Z No. of bitstreams: 1 HalineTerezaMatiasDeLimaCosta_DISSERT.pdf: 2192045 bytes, checksum: fd4867171ed1080dec47c90260404de7 (MD5) / Approved for entry into archive by Arlan Eloi Leite Silva (eloihistoriador@yahoo.com.br) on 2017-10-11T23:11:44Z (GMT) No. of bitstreams: 1 HalineTerezaMatiasDeLimaCosta_DISSERT.pdf: 2192045 bytes, checksum: fd4867171ed1080dec47c90260404de7 (MD5) / Made available in DSpace on 2017-10-11T23:11:45Z (GMT). No. of bitstreams: 1 HalineTerezaMatiasDeLimaCosta_DISSERT.pdf: 2192045 bytes, checksum: fd4867171ed1080dec47c90260404de7 (MD5) Previous issue date: 2017-06-30 / INTRODU??O: Diversos estudos t?m mostrado que um n?mero significativo de medicamentos prescritos a pacientes pedi?tricos s?o off-label ou n?o licenciados, mas existe pouca informa??o sobre o uso destes medicamentos em unidades de terapia intensiva neonatal (UTIN), assim como estudos sobre fatores de risco para potenciais intera??es medicamento-medicamento (IMM). OBJETIVO: Identificar a prescri??o de medicamentos off-label e n?o licenciados utilizados em rec?m-nascidos (RN) hospitalizados em UTIN, al?m de avaliar frequ?ncia de IMM e seus fatores de risco. METODOLOGIA: Coorte prospectiva, no qual foram inclu?dos neonatos admitidos consecutivamente na UTIN da Maternidade Escola Janu?rio Cicco com pelo menos um medicamento prescrito e tempo de interna??o superior a 24 horas. Dados cl?nicos e farmacoterap?uticos dos neonatos foram coletados durante toda a interna??o, sendo a classifica??o dos medicamentos em off-label e n?o licenciados realizada de acordo com crit?rios da Food and Drug Administration atrav?s da base DrugDex-Micromedex?, a qual tamb?m foi utilizada na classifica??o das IMM, cujos fatores de risco foram identificados por regress?o log?stica. RESULTADOS: Entre agosto de 2015 e agosto de 2016 foram analisados 17421 itens medicamentosos em 3935 prescri??es de 220 neonatos, dos quais 96,4% foram expostos a medicamentos off-label e 66,8% a n?o licenciados. Mais de 70% dos prematuros e RN com menos de 2000g foram submetidos ? farmacoterapia com medicamentos off-label e mais de 50% aos n?o licenciados. Os anti-infecciosos para uso sist?mico foram o grupo farmacol?gico mais prescrito de forma off-label,sendo o fentanil (n=1358) e a gentamicina (n= 1197) os medicamentos com maior preval?ncia de uso off-label para RN. A cafe?na (n=1226) foi o medicamento n?o licenciado mais prescrito, seguido pelos agentes cardiovasculares (n=648) modificados pela enfermagem. Em 42,3% (n= 1665) das prescri??es foram detectadas IMM, cujos fatores de risco para IMM importantes foram o n?mero de medicamentos (OR 1,60, p<0,001), parto ces?reo (OR 2,68, p=0,06) e idade gestacional (OR 1,03, p= 0,002). CONCLUS?ES: RN em terapia intensiva ? submetido ? alta taxa de prescri??o e exposi??o a medicamentos off-label e n?o licenciados, sendo os mais frequentes os anti-infecciosos de uso sist?mico e os medicamentos atuantes no sistema nervoso, e tamb?m uma elevada incid?ncia de IMM, consistindo o n?mero de medicamentos prescritos, parto ces?reo e a idade gestacional os principais fatores de risco para IMM. / INTRODUCTION: Several studies have shown that a significant number of drugs prescribed to pediatric patients are off-label or unlicensed, but there is little information about the use of these drugs in neonatal intensive care units (NICUs), as well as studies about risk factors for drug-drug interactions (DDI). PURPOSE: To evaluate the use of off-label and unlicensed drugs in a Brazilian NICU of a teaching maternity hospital specialized in high risk pregnancy, and the frequency of DDI and associated risk factors. METHODS: A prospective cohort study was conducted between august 2015 and august 2016. All newborns admitted consecutively in the NICU of the Maternity School Janu?rio Cicco for over 24 hours and who had at least one medication prescribed were included. Demographic and clinical data were collected, as well as all medications prescribed during hospitalization. The classification of off-label and unlicensed drugs for the neonatal population according to the Food and Drug Administration criteria was done based on the DrugDex-Micromedex? database, which was also used for the classification of DDI. Logistic regression was used for the analysis of risk factors. RESULTS: A total of 17421 prescriptions items were analyzed in 3935 prescriptions of 220 newborns, of whom 96.4% were exposed to off-label medications and 66.8% to unlicensed drugs. More than 70% of premature and neonates with birth weight less than 2000g were submitted to off-label medicines and more than 50% to unlicensed. The anti-infectives for systemic use were the most prescribed off-label pharmacological group and the drugs most frequently classified as off-label for newborn were Fentanil (n= 1358) and gentamicin (n= 1197). Caffeine (n = 1226) was the most prescribed unlicensed drug, followed by cardiovascular agents (n= 648) modified by nursing. DDIs were found in 42,3% (n= 1665) of prescriptions , with number of drugs (OR 1.60, p<0,001), cesarean delivery (OR 2.68, p = 0,06) and gestational age (OR 1.03, p = 0,002) as risk factors for major DDI. CONCLUSION: Neonates in intensive care units have a high rate of prescriptions and exposure to off-label and unlicensed drugs, with antimicrobials for systemic use and drugs action on nervous system as the most frequently prescribed, as well as a high incidence of DDI, with number of medicines, cesarean delivery and gestational age being risk factors for major DDI.